TMDX stock forecast
Our latest prediction for TransMedics Group, Inc.'s stock price was made on the Dec. 9, 2019 when the stock price was at 20.00$.
In the short term (2weeks), TMDX's stock price should underperform the market by -8.61%. During that period the price should oscillate between -13.54% and +9.62%.
In the medium term (3months), TMDX's stock price should underperform the market by -18.86%. During that period the price should oscillate between -40.75% and +20.04%.Get email alerts
About TransMedics Group, Inc.
TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.
At the moment the company generates 21M USD in revenues.
On its last earning announcement, the company reported a loss of -1.49$ per share.
The book value per share is 3.00$
Three months stock forecastDec. 9, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|